183 related articles for article (PubMed ID: 38236627)
21. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer risk prediction based on clinical factors and prostate-specific antigen.
Hwang T; Oh H; Lee JA; Kim EJ
BMC Urol; 2023 Jun; 23(1):100. PubMed ID: 37270476
[TBL] [Abstract][Full Text] [Related]
23. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
24. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
25. Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men.
Dankner R; Boffetta P; Keinan-Boker L; Balicer RD; Berlin A; Olmer L; Murad H; Silverman B; Hoshen M; Freedman LS
Diabetologia; 2016 Aug; 59(8):1683-91. PubMed ID: 27189066
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
28. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
29. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
[TBL] [Abstract][Full Text] [Related]
30. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Wyler SF; Chun FF; Recker F; Kwiatkowski M
World J Urol; 2015 Aug; 33(8):1189-96. PubMed ID: 25358675
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
32. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
33. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
34. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
35. [The prostate cancer precision screening program: a preliminary report after recruitment of 2 159 men].
Gu CY; Qin XJ; Huang YQ; Zhu Y; Dai B; Ye DW
Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(42):3292-3297. PubMed ID: 31715663
[No Abstract] [Full Text] [Related]
36. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
[TBL] [Abstract][Full Text] [Related]
37. PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium.
Song ZJ; Qian JK; Yang Y; Wu HX; Wang MY; Jiang SY; Wang FB; Zhang W; Chen R;
Asian J Androl; 2021; 23(3):300-305. PubMed ID: 33208562
[TBL] [Abstract][Full Text] [Related]
38. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
40. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
